Sandoz has announced the
US debut of Zarxio (filgrastimsndz),
the first biosimilar to be
approved by the FDA, with the
same indications as oncology drug
Neupogen.
Zarxio was approved via a new
pathway established under the US
Biologics Price Competition and
Innovation Act, based on a package
of analytical, clinical and nonclinical
data which confirmed it is “highly
similar with no clinically meaningful
differences to the US-licensed
reference product”.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Sep 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Sep 15
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.